Biomedical Research Service


  • Google
Home
Citations
Metabolites
Enzymes
Recipes
Contact Us
Order

GABA Aminotransferase Assay Kit



(GABAT Assay Kit)



Product Description:

Gamma-aminobutyrate aminotransferase (GABAT) is a pyridoxal phosphate-dependent enzyme involved in the degradation of the inhibitory neurotransmitter GABA. GABAT converts GABA and alpha-ketoglutarate to glutamate and succinic semialdehyde. The fine balance of the GABAergic inhibitory tone in the CNS is critical for countering the excitatory pathway mediated by L-glutamate. Thus, therapeutic targeting of the GABA system covers a broad spectrum of neurological and psychiatric disorders, and GABAT is a validated target for epilepsy therapy because inhibition of the enzyme raises GABA concentrations in the brain. GABAT has been found in a wide variety of species (microorganisms, plants and invertebrates) in addition to vertebrates. GABAT activity is also demonstrable in hepatic tissue in addition to brain. GABAT deficiency is listed as a “rare disease" by the Office of Rare Disease of the NIH. The GABAT activity assay is based on sequential transamination reaction and glutamate dehydrogenase reaction, which couples the reduction of INT to INT-formazan (molar extinction coefficient = 18/mM-cm at 492 nm), allowing for sensitive detection of GABAT enzyme activity in crude tissue samples. Assay solutions are stable for several years if stored and handled properly.

#GABA Aminotransferase


Kit Components:

GABAT Substrate: 5 ml, store at -80°C

TA Assay Solution: 10 ml, store at -80°C (for 200 wells)

10x Cell Lysis Solution: 25 ml, store at 4ºC


SDS:

TX-100, DMSO, INT, Hepes


Related Kits:

AST Assay, HK Enzyme Assay, GAPDH Enzyme Assay,

LDH Enzyme Assay, PDH Enzyme Assay, ALT Assay


Citation:

Besse et al

Personalized medicine approach confirms a milder case of ABAT deficiency

Molecular Brain 9: 93, 2016


Zhao et al

High methylation of the 4-aminobutyrate aminotransferase gene predicts a poor prognosis in patients with myelodysplastic syndrome

International J of Oncology 54: 491-504, 2019